Everything below concerns Immunomodulatory peptide. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-09-10. Where a claim depends on a specific study, the study is described rather than over-claimed.
The peptide is generated in cells by cleavage of prothymosin alpha, a larger acidic protein encoded by the PTMA gene. Prothymosin alpha is expressed in many tissues, not only in the thymus, and its functions include nuclear roles in chromatin-related processes. The 28-residue fragment corresponds to the N-terminal portion of that precursor. How the cleavage occurs and how the fragment's concentration is regulated remain open questions; circulating amounts are small and difficult to measure reliably with routine assays.
Thymosin alpha 1 is a short peptide first isolated from bovine thymus tissue in the early 1970s during fractionation work aimed at identifying factors that influence T cell development. It belongs to a family of acidic thymic peptides, and the original preparations contained several components that were later separated by chromatography. The compound is now produced synthetically rather than extracted from tissue, which removes batch variability tied to animal sourcing. Researchers describe it as an immunomodulatory peptide because laboratory studies show effects on several cell types of the innate and adaptive immune systems.
Immune signaling studies link thymosin alpha 1 to Toll-like receptor pathways, particularly TLR2 and TLR9, on dendritic cells and other antigen-presenting cells. Activation of these receptors promotes maturation of T cells and increases natural killer cell activity. The peptide shifts cytokine output toward a T helper 1 profile, raising interferon gamma and interleukin 2 while modulating interleukin 10. Whether these effects translate into clinical benefit for any specific disease remains a subject of debate. Reported outcomes vary across trials and populations.
Thymosin alpha 1 is approved as a medicine in several countries, including Italy and China, for indications such as chronic hepatitis B and as an immune adjuvant. It is not approved by the United States Food and Drug Administration as a therapeutic product. In research settings the peptide appears in studies of sepsis, vaccine response, and oncology support, often with mixed or inconclusive results. The evidence base is uneven, and reviews note that many trials were small. Regulatory status therefore differs widely between jurisdictions.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Acetylated peptide | N-terminal acetyl group blocks aminopeptidase attack |
| Residue count | 28 amino acids | Matches the N-terminus of prothymosin alpha |
| Molecular mass | About 3,108 Da | Value for the free, unmodified peptide |
| Isoelectric point | Approximately 4.2 | Acidic; net negative charge at neutral pH |
| Encoding gene | PTMA | Human gene for the precursor protein |
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Results across trials have been mixed, and several studies were small or conducted under differing protocols. Regulatory status varies by country, and the compound is not approved in every jurisdiction where it is studied. Evidence for any single indication should be read with attention to sample size and endpoint choice.
Thymosin alpha-1 is a 28-residue peptide first isolated from thymus tissue in the 1970s. It corresponds to the N-terminal portion of thymosin beta-4, from which it is cleaved in vivo. The peptide carries an acetyl group at its N-terminus, a modification that affects its charge and stability. Synthetic material produced by solid-phase peptide synthesis is chemically identical to the natural fragment and is the form used in research and clinical studies.
The peptide was identified during work in the 1970s on thymosin fraction 5, a partially purified extract of calf thymus. Investigators separated that mixture and characterized individual components, one of which they named thymosin alpha-1. The same compound later received the international nonproprietary name thymalfasin. Commercial material is produced by solid-phase peptide synthesis rather than by extraction, so synthetic and natural forms share an identical sequence. Naming conventions vary across the literature, and readers should distinguish the alpha-1 peptide from other thymosins that have unrelated sequences and functions.
Thymosin beta-4 is a separate 43-residue peptide that binds actin and participates in cell migration; it shares no sequence similarity with thymosin alpha-1 despite the common family name. Other preparative materials, such as thymosin fraction 5 and thymopoietin, contain distinct mixtures or peptides. The shared thymosin label reflects the tissue of origin used in early purification, not a common structural core. Treating these molecules as interchangeable is a frequent source of confusion in laboratory reports and in popular summaries alike.
Immunological studies connect the peptide to multiple parts of the immune response. It has been reported to engage Toll-like receptor signaling, to promote dendritic cell maturation, and to influence the balance of T helper cell subsets. Changes in natural killer cell activity and in cytokine release appear in cell culture and animal models. These observations describe broad immunomodulatory behavior rather than a single defined receptor target, and the primary molecular interaction has not been settled.
Thymosin alpha-1 is a synthetic 28-amino-acid peptide whose sequence was first identified in extracts of bovine thymus tissue during the 1970s. The chain carries an acetyl group on its N-terminal serine. Its acidic residue content is high, which produces strong water solubility and an isoelectric point well below neutrality. Material supplied for laboratory and clinical use is manufactured by solid-phase peptide synthesis rather than purified from animal tissue. Different salt forms, such as the acetate, alter the counter-ion content without changing the peptide backbone.
Clinical research has examined the peptide in chronic hepatitis B and C, as a vaccine adjuvant, and in sepsis and oncology settings. Findings across trials are mixed; some report changes in selected immune markers, while others find no clear clinical benefit. Many studies are small and define outcomes differently, which limits comparison. Regulatory approval is confined to a few countries, and the compound is not an approved drug in the United States or most of Europe.
Overall evidence quality varies considerably. A large share of published reports come from single centers, rely on surrogate immunological markers, or lack adequate control groups. Systematic reviews have highlighted this heterogeneity as a barrier to pooling results. Open questions include which patients, if any, might benefit, what treatment duration is appropriate, and whether any effect is independent of standard care. The peptide is often described as an immune modulator rather than a therapy for one disease, which complicates confirmatory trial design.
== Y-axis: signal intensity == The y-axis of a mass spectrum represents signal intensity of the ions. When using counting detectors the intensity is often measured in counts per second (cps). When using analog detection electronics the intensity is typically measured in volts. In FTICR and Orbitraps the frequency domain signal (the y-axis) is related to the power (~amplitude squared) of the signal sine wave (often reduced to an rms power); however, the axis is usually not labeled as such for many reasons. In most forms of mass spectrometry, the intensity of ion current measured by the spectrometer does not accurately represent relative abundance, but correlates loosely with it. Therefore, it is common to label the y-axis with "arbitrary units".
Ten years earlier, in 2005, the Minnesota Department of Health notified the federal Centers for Disease Control and Prevention (CDC) that four cases of Salmonella typhimurium (S. typhimurium) with an indistinguishable pulsed-field gel electrophoresis (PFGE) subtype (CDC PulseNet pattern JPXX01.1173) had been identified. The only common exposure among the four ill individuals was that all had eaten at one of two Cold Stone Creamery stores. All cases had eaten cake batter flavor ice cream in the week before the onset of symptoms. After a thorough investigation, 25 cases were identified in nine states (Minnesota, Oregon, Washington, Virginia, Ohio, California, Illinois, Massachusetts, Michigan, and Pennsylvania); 24 reported eating cake batter ice cream from Cold Stone Creamery.
Mirroring the upwards trend in the volume of opioid pain relievers prescribed was an increase in admissions for substance use disorder treatments and opioid-related deaths. This illustrates how legitimate clinical prescriptions of pain relievers were being diverted through an illegitimate market, leading to misuse, addiction, and death. With the increase in volume, the potency of opioids also increased. By 2002, one in six opioid users was prescribed drugs more powerful than morphine. By 2012, the ratio had doubled to one in three. The most commonly prescribed opioids were oxycodone and hydrocodone.
Popular party substances have been reported by users to consist of aphrodisiac properties because of their enhancing effects with sexual pleasure. Ecstasy users have reported an increase in sexual desire and sexual pleasure; however, there have been reports of delayed orgasm in both sexes and erectile difficulties in men. Poppers, containing drugs for inhalation, have been linked to increased sexual pleasure. Known adverse effects are headaches, nausea, and temporary erectile difficulties.
Sources: en.wikipedia.org
=== Supersonic spray === Supersonic acceleration of droplets through a Laval nozzle was used to deposit reduced graphene oxide on a substrate. The energy of the impact rearranges those carbon atoms into flawless graphene.
==== Vabicaserin and aripiprazole ==== Vabicaserin has a high affinity for 5-HT2C receptors and low affinity for 5-HT2B and 5-HT2A receptors. Vabicaserin is a full agonist with approximately 4-fold greater selectivity for 5-HT2C over these related receptors, in terms of binding affinity. Vabicacserin is a full agonist in stimulating the 5-HT2C receptor; it was discovered when a class of tetrahydroquinoline-fused diazepines were being researched as possible potent 5-HT2C receptor agonists. As of 2012, vabicaserin is in clinical trials for the treatment of schizophrenia. Long-term administration of vabicaserin significantly decreased the number of spontaneously active mesocorticolimbic dopamine neurons without affecting nigrostriatal dopamine neurons, consistent with effects of atypical antipsychotic agents. The outcome of clinical studies for vabicaserin may reveal whether 5-HT2C receptors can be possible targets for the treatment of schizophrenia. Aripiprazole is also a mild partial agonist of 5HT2C receptor.
Operation began with the Type T.3026 transmitter sending a pulse of radio energy into the transmission antennas from a hut beside the towers. Each station had two T.3026s, one active and one standby. The signal filled space in front of the antenna, flooding the entire area. Due to the transmission effects of the multiple stacked antennas, the signal was most strong directly along the line of shoot, and dwindled on either side. An area about 50 degrees to either side of the line was filled with enough energy to make detection practical. The Type T.3026 transmitter was provided by Metropolitan-Vickers, based on a design used for a BBC transmitter at Rugby. A unique feature of the design was the "demountable" valves, which could be opened for service, and had to be connected to an oil diffusion vacuum pump for continual evacuation while in use. The valves were able to operate at one of four selected frequencies between 20 and 55 MHz, and switched from one to another in 15 seconds. To produce the short pulses of signal, the transmitter consisted of Hartley oscillators feeding a pair of tetrode amplifier valves. The tetrodes were switched on and off by a pair of mercury vapour thyratrons connected to a timing circuit, the output of which biased the control and screen grids of the tetrode positively while a bias signal kept it normally turned off. Stations were arranged so their fan-shaped broadcast patterns slightly overlapped to cover gaps between the stations.
== Range and habitat == The neon tetra is found in the western and northern Amazon basin in southeastern Colombia, eastern Peru, and western Brazil. It lives in waters with a temperature between 20 and 28 °C (68–82 °F) and pH 4–7.5. It has a preference for acidic blackwater streams, but also occurs in transparent clearwater streams. It is not found in the whitewater rivers. UN FAO considers P. innesi an introduced species in Singapore and the United States. FAO considers its introduction to Singapore to be ecologically and socioeconomically beneficial, but it is not established there.
The TV show Inside Amy Schumer premiered on Comedy Central on April 30, 2013. Inside Amy Schumer was picked up for a second season that began in 2014. A behind-the-scenes miniseries entitled Behind Amy Schumer premiered in 2012. The third season premiered on April 21, 2015, with a fourth season ordered the same day. In 2014, Schumer embarked on her Back Door Tour to promote the second season of her show. The show was closed by Bridget Everett, whom Schumer cites as her favorite live performer. She also appeared as a guest on an episode of comedian Jerry Seinfeld's Internet series Comedians in Cars Getting Coffee in 2014. She hosted the 2015 MTV Movie Awards, which took place on April 11. Schumer wrote and played her first leading film role in Trainwreck, co-starring Bill Hader, which was released on July 17, 2015. In August 2015, Jennifer Lawrence said she and Schumer planned to co-star in a film for which they and Schumer's sister Kim were co-writing a screenplay. However, Schumer later revealed the project was on the "back burner". Schumer performed as opening act for Madonna on three New York City dates of the singer's Rebel Heart Tour in September 2015. On October 17, 2015, Schumer's comedy special Amy Schumer: Live at the Apollo premiered on HBO. In 2016, it was nominated for three Primetime Emmy Awards for Outstanding Variety Special, Writing, and Directing. It also garnered her a nomination for the Grammy Award for Best Comedy Album. Schumer started her first world tour on August 26 in Dublin.
Sources: en.wikipedia.org
=== Sponges === The skeleton of sponges consists of microscopic calcareous or siliceous spicules. The demosponges include 90% of all species of sponges. Their "skeletons" are made of spicules consisting of fibers of the protein spongin, the mineral silica, or both. Where spicules of silica are present, they have a different shape from those in the otherwise similar glass sponges.
In a covalent bond, one or more pairs of valence electrons are shared by two atoms: the resulting electrically neutral group of bonded atoms is termed a molecule. Atoms will share valence electrons in such a way as to create a noble gas electron configuration (eight electrons in their outermost shell) for each atom. Atoms that tend to combine in such a way that they each have eight electrons in their valence shell are said to follow the octet rule. However, some elements like hydrogen and lithium need only two electrons in their outermost shell to attain this stable configuration; these atoms are said to follow the duet rule, and in this way they are reaching the electron configuration of the noble gas helium, which has two electrons in its outer shell. Similarly, theories from classical physics can be used to predict many ionic structures. With more complicated compounds, such as metal complexes, valence bond theory is less applicable and alternative approaches, such as the molecular orbital theory, are generally used.
From 2012 to 2022, the share of the market value of private sector firms in China's top listed companies increased from 10% to over 40%. He has overseen the relaxation of restrictions on foreign direct investment (FDI) and increased cross-border holdings of stocks and bonds. His administration made it easier for banks to issue mortgages, increased foreign participation in the bond market, and increased the national currency renminbi's global role, helping it to join IMF's basket of special drawing right. Xi launched the Shanghai Free-Trade Zone in 2013. In 2018, Xi announced the Shanghai Stock Exchange STAR Market, which opened in 2019. He also led the establishment of the Hainan Free Trade Port. In 2020, The Wall Street Journal reported that Xi ordered a halt to Ant Group's initial public offering (IPO), in reaction to its founder Jack Ma criticizing government regulation in finance. Under Xi, government guidance funds, public-private investment funds set up by or for government bodies, have raised more than $900 billion for early funding to companies that work in sectors the government deems as strategic. Xi's administration has overseen a decrease in offshore IPOs by Chinese companies, with most Chinese IPOs taking place either in Shanghai or Shenzhen as of 2022, and has increasingly directed funding to IPOs of companies that works in sectors it deems as strategic, including electric vehicles, biotechnology, renewable energy, artificial intelligence, semiconductors and other high-technology manufacturing.
=== Eyes === A buffered PVP-I solution of 2.5% concentration can be used for prevention of neonatal conjunctivitis, especially if it is caused by Neisseria gonorrhoeae, or Chlamydia trachomatis. It is unclear whether PVP-I is more effective in reducing the number of cases of conjunctivitis in neonates over other methods. PVP-I appears to be very suitable for this purpose because, unlike other substances, it is also efficient against fungi and viruses (including HIV and Herpes simplex).
Sources: en.wikipedia.org
Thymosin fraction 5 is a mixture of many peptides obtained from thymus tissue, while thymosin alpha 1 is a single defined 28-residue molecule. The two names appear together in older literature because the purified peptide was first obtained from that mixture.
The precursor, prothymosin alpha, is encoded by the PTMA gene in humans. The 28-residue peptide corresponds to the N-terminal segment released from that larger protein.
It is produced as a fragment of prothymosin alpha and is present in many tissues. Circulating concentrations are low, which makes routine measurement difficult.
It is a chain of 28 amino acids, with an acetyl group attached to the first serine residue. The synthetic version replicates this sequence. Its molecular mass is about 3,108 daltons.